Aptose生物科学 APTO 深 沪
等待开盘 08-16 09:30:00 美东时间
1.71
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.71
- 总市值 436.46万
- 52周最高 42.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.35
- 委 比 0.00%
- 总股本 255.24万
- 历史最高 5032.80
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.30
- 每 手 1
- 风险率 3.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aptose Biosciences Secures $2M Advance for AML Therapy
The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). On July ...
07-16 05:30
Delisting of Securities from The Nasdaq Stock Market
The Nasdaq Stock Market announced on July 11, 2025, that it will delist the securities of multiple companies, including NKGen Biotech, Inc., Aquaron Acquisition Corp., Bannix Acquisition Corp., Avenue Therapeutics, Inc., WinVest Acquisition Corp., IMAC Holdings, Inc., Lytus Technologies Holdings PTV Ltd., Luokung Technology Corp., Aptose Biosciences, Inc., Virpax Pharmaceuticals, Inc., Phoenix Motor Inc., Denali Capital Acquisition Corp., Thunder...
07-11 20:05
Aptose Biosciences Upgrades to OTCQB Market Listing
An update from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosc...
07-01 20:37
Aptose Biosciences Secures $8.5M Loan for AML Therapy
Aptose Biosciences ( ($TSE:APS) ) just unveiled an update. On June 20, 2025, Ap...
06-20 20:28
Aptose Biosciences Begins 120 mg Dosing in TUSCANY Trial
Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. On May 20, 2025, ...
05-20 19:59
Aptose’s TUSCANY Trial Data to be Presented at EHA 2025
Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Bioscience...
05-15 01:38
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence
Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. Aptose Bioscience...
05-08 19:57
Aptose common shares to delist from Nasdaq
Aptose Biosciences (NASDAQ:APTO) announced that Nasdaq has determined to delist the common shares of the company, as of April 2, 2025. Under the terms of the Nasdaq’s decision in this matter, the comp...
04-01 20:46
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
Aptose Biosciences GAAP EPS of -$36.38
Aptose Biosciences press release (NASDAQ:APTO): FY GAAP EPS of -$36.38. Total cash, cash equivalents and restricted cash equivalents as of December 31, 2024, were $6.7 million. Based on current operat...
03-28 20:17
